BC-1215

Cat. No.:	HY-117937
CAS No.:	1507370-20-8
Molecular Formula:	$C_{26}H_{26}N_4$
Molecular Weight:	394.51
Target:	Ligands for E3 Ligase
Pathway:	PROTAC
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 12.5 mg/mL (31.68 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5348 mL	12.6740 mL	25.3479 mL
	5 mM	0.5070 mL	2.5348 mL	5.0696 mL
	10 mM	0.2535 mL	1.2674 mL	2.5348 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BC-1215 is an inhibitor of F-box protein 3 (FBXO3, a ubiquitin E3 ligase component, IC_{50}=0.9 μg/mL for IL-1β release). BC-1215 decreases Fbxo3-Fbxl2 interaction and prevents SCF^{Fbxo3} catalyzed Fbxl2 ubiquitination. BC-1215 inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1–TRAF6. BC-1215, interacts with ApaG to profoundly inhibit secretion of a broad spectrum of TH1 panel cytokines from human PBMC[1].

REFERENCES

[1]. Chen BB, et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulateinflammation. Nat Immunol. 2013 May;14(5):470-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA